Oncolipsy

Oncolipsy is a cutting-edge product line offering market-ready, blood-based molecular diagnostic kits designed for oncological applications. Pharmassist’s R&D department is dedicated to the development and commercialization of innovative molecular in vitro diagnostic products for the oncology field. Since 2014, the company has focused its efforts on developing CE-IVD PCR kits, establishing a clear strategy for securing proprietary assets through patents and trademarks. To date, Pharmassist has successfully acquired nine granted patents through PCT and national applications in major markets, including Europe, the USA, Canada, Israel, India, China, Japan, and Hong Kong. The company has developed two novel molecular diagnostic kits currently available on the market. These PCR-based tests, certified with CE-IVD, are designed to detect cancer-related biomarkers in both peripheral blood and tumor samples from cancer patients. These diagnostic kits have been developed and manufactured at Pharmassist’s privately owned facilities, which adhere to the highest quality standards. The facilities are certified according to ISO 13485, ISO 9001, and GMP requirements, ensuring the reliability and excellence of the products.